Reductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide

FRIDAY, Oct. 6, 2023 -- For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight compared with insulin lispro, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news